Edgestream Partners L.P. Has $1.73 Million Stake in Zoetis Inc. $ZTS

Edgestream Partners L.P. reduced its holdings in Zoetis Inc. (NYSE:ZTS) by 80.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,110 shares of the company’s stock after selling 44,509 shares during the period. Edgestream Partners L.P.’s holdings in Zoetis were worth $1,733,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of ZTS. Savvy Advisors Inc. raised its position in shares of Zoetis by 54.0% in the 2nd quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock valued at $495,000 after acquiring an additional 1,114 shares during the period. Sound Income Strategies LLC increased its stake in Zoetis by 54.3% in the second quarter. Sound Income Strategies LLC now owns 432 shares of the company’s stock valued at $67,000 after purchasing an additional 152 shares in the last quarter. Canoe Financial LP raised its holdings in Zoetis by 859.0% in the second quarter. Canoe Financial LP now owns 13,369 shares of the company’s stock worth $2,085,000 after purchasing an additional 11,975 shares during the period. Strs Ohio acquired a new stake in Zoetis in the first quarter worth $22,891,000. Finally, Chicago Partners Investment Group LLC boosted its position in shares of Zoetis by 67.0% during the second quarter. Chicago Partners Investment Group LLC now owns 4,886 shares of the company’s stock worth $750,000 after purchasing an additional 1,961 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 1.4%

NYSE:ZTS opened at $118.69 on Friday. The stock has a 50-day simple moving average of $133.77 and a 200 day simple moving average of $147.78. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $181.85. The company has a market cap of $52.31 billion, a PE ratio of 19.98, a PEG ratio of 2.50 and a beta of 0.97. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The business’s revenue was up .5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 2nd. Investors of record on Friday, October 31st were given a $0.50 dividend. The ex-dividend date of this dividend was Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is 33.67%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ZTS shares. BTIG Research reaffirmed a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research note on Wednesday. JPMorgan Chase & Co. dropped their price target on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. UBS Group lowered their target price on Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research note on Wednesday, November 5th. Finally, Piper Sandler lifted their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Six research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $178.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.